{"access":{"can_view":true,"can_edit":false,"can_remove":false,"can_add":false,"can_publish":false,"can_get_doi":false,"can_share":true,"can_move":true,"can_move_outside":true,"can_transfer":true,"can_download":true,"limited_run":false,"limited_private_links":false,"limited_blind_links":false,"is_locked":false},"authors":[{"name":"Jorge Machado Alba","affiliation":"Universidad Tecnologica de Pereira - Audifarma SA","affiliation_url":null,"username":"jorge--------machado-alba","link":null,"user_image_file":{"guid":"00000000000000000000000000000001","file_name":"avatar.png","url":"https://www.protocols.io/img/avatars/001.png","mime":"image/png","size":0,"width":100,"height":100,"avg_color":"","scan_status":0,"created_at":0},"note":"","is_verified_user":true}],"before_start":"","book_chapter":null,"can_accept_authorship":false,"can_be_copied":true,"can_claim_authorship":false,"can_manage_keywords":true,"can_remove_fork":false,"can_sign":false,"child_steps":{},"cited_protocols":[],"collection_items":[],"created_on":1727476255,"creator":{"name":"Jorge Machado Alba","affiliation":"Universidad Tecnologica de Pereira - Audifarma SA","affiliation_url":null,"username":"jorge--------machado-alba","link":null,"user_image_file":{"guid":"00000000000000000000000000000001","file_name":"avatar.png","url":"https://www.protocols.io/img/avatars/001.png","mime":"image/png","size":0,"width":100,"height":100,"avg_color":"","scan_status":0,"created_at":0},"badges":[{"id":4,"name":"Gold power author!","image":{"source":"/img/badges/gold.svg","placeholder":"/img/badges/gold.svg"}}],"affiliations":[{"affiliation":"Universidad Tecnologica de Pereira - Audifarma SA","url":null,"job_title":null,"is_default":true}]},"cross_cloud_origin":null,"description":"{\"blocks\":[{\"key\":\"76rsa\",\"text\":\"Introduction:\\nInflammatory arthritis is related to disability, chronic pain, and premature\\ndeath. A lack of treatment persistence leads to poor control of symptoms, inflammation,\\nand joint damage, thereby worsening quality of life.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"italic\",\"offset\":0,\"length\":13}],\"entityRanges\":[],\"data\":{}},{\"key\":\"ahmj9\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"italic\",\"offset\":0,\"length\":1}],\"entityRanges\":[],\"data\":{}},{\"key\":\"4rgg7\",\"text\":\"Objective: To\\ndetermine the effectiveness of antirheumatic drug treatment and the persistence\\nof use in Colombian patients diagnosed with rheumatoid arthritis (RA),\\npsoriatic arthritis (PsA), ankylosing spondyloarthritis (AS), and juvenile\\nrheumatoid arthritis (JIA) after the failure of conventional disease-modifying\\nantirheumatic drugs. (cDMARDs).\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"italic\",\"offset\":0,\"length\":9}],\"entityRanges\":[],\"data\":{}},{\"key\":\"d7gne\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"italic\",\"offset\":0,\"length\":1}],\"entityRanges\":[],\"data\":{}},{\"key\":\"bb3n2\",\"text\":\"Methods: In this retrospective\\ndescriptive study, patients who were diagnosed with RA, PsA, AS, or JIA; were\\ntreated at a center specializing in rheumatological diseases; who started their\\nfirst treatment with biological DMARDs (bDMARDs) or tofacitinib between\\nFebruary 2016 and December 2019; and who were followed up until the\\ndiscontinuation of treatment or 24 months were evaluated.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"italic\",\"offset\":0,\"length\":8}],\"entityRanges\":[],\"data\":{}},{\"key\":\"e3gqp\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"italic\",\"offset\":0,\"length\":1}],\"entityRanges\":[],\"data\":{}},{\"key\":\"dnsu9\",\"text\":\"Results: A total of 426\\npatients were included; 78.8% were women, and the mean age was 50.2±14.1 years.\\nThe majority had a diagnosis of RA (71.8%). A total of 89.9% had received\\ncDMARDs, and 77.2% had received glucocorticoids. The most frequently initiated\\nbDMARDs were rituximab (31.2%), etanercept (23.0%), and adalimumab (14.6%). A\\ntotal of 80.3% of patients received concomitant cDMARDs. During an average\\nfollow-up of 635.2±189.6 days, 12.9% of patients had changes in their treatment\\nregimen, 26.3% had interruptions in their treatment regimen, and 23.9%\\ndiscontinued bDMARDs or tofacitinib. Patients who received concomitant cDMARDs\\nwere more likely to continue their biological therapy (odds ratio: 8.50; 95% confidence\\ninterval: 3.49-20.73; p\\u003c0.001).\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"italic\",\"offset\":0,\"length\":7}],\"entityRanges\":[],\"data\":{}},{\"key\":\"dobu5\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"italic\",\"offset\":0,\"length\":1}],\"entityRanges\":[],\"data\":{}},{\"key\":\"c4oj5\",\"text\":\"Conclusions: Follow-up\\nevaluation of this group of patients revealed that they were treated mainly\\nwith non-TNF-α inhibitors associated with cDMARDs, and a low proportion of the\\npatients had changes in therapy, although one-quarter had treatment interruptions\\nor discontinuations.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"italic\",\"offset\":0,\"length\":11}],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","disclaimer":"{\"blocks\":[{\"key\":\"2r4k8\",\"text\":\"This research received funds of Pfizer Colombia\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","document":"","documents":[{"id":502601,"guid":"","type_id":0,"filename":"","key":"","color":"","height":0,"width":0,"is_document":null,"original_file_id":null,"thumb_url":"https://www.protocols.io/img/extensions/xlsx.png","size":367179,"is_private":0,"is_new":0,"ofn":"BD GH Colombia Anon.xlsx","url":"https://content.protocols.io/files/rk4jbamqp.xlsx","bucket_name":null,"s3_webp_url":"","file_id":502601}],"doi":"dx.doi.org/10.17504/protocols.io.kqdg32z31v25/v1","doi_status":2,"ethics_statement":"","fork_id":null,"fork_info":null,"fork_info_status":"not_fork","forks":[],"funders":[{"funder_name":"Pfizer ","grant_id":"Contrato No. 2021-263"}],"groups":[{"id":5217,"uri":"utpaudifarma1","title":"UTP-Audifarma","is_public":true,"image":{"source":"https://s3.amazonaws.com/protocols-files/files/82C629E42A8011ECAB100A58A9FEAC02-placeholder.png","placeholder":"https://s3.amazonaws.com/protocols-files/files/82C629E42A8011ECAB100A58A9FEAC02-placeholder.png"},"tech_support":{"email":null,"phone":null,"use_email":false,"hide_contact":false,"url":null}}],"guid":"70F3B2F743A24948A15464FD74E932CB","guidelines":"","has_references":false,"has_step_reagents":false,"has_versions":false,"id":108568,"image":{"source":"https://www.protocols.io/img/default_protocol.png","webp_source":null,"placeholder":"https://www.protocols.io/img/default_protocol.png","webp_placeholder":null},"image_attribution":"","in_trash":false,"is_bookmarked":false,"is_contact_suspended":false,"is_content_confidential":false,"is_content_warning":false,"is_doi_reserved":true,"is_in_pending_publishing":false,"is_in_transfer":false,"is_owner":true,"is_research":true,"is_retracted":false,"is_shared_directly":false,"is_subprotocol":null,"is_unlisted":false,"item_id":1302689,"journal":null,"journals":[],"keywords":"Disease-Modifying Antirheumatic Drugs; Persistence, Medication; Arthritis, Rheumatoid; Pharmacoepidemiology; Colombia","last_modified":1727476824,"link":"","location":null,"manuscript_citation":"","materials":[],"materials_text":"","ownership_history":null,"parent_collections":[],"parent_protocols":[],"peer_reviewed":false,"protocol_references":"","public":true,"public_fork_note":"","published_on":1727476824,"references":[],"related_equipments":[],"related_materials":[],"reserved_doi":"10.17504/protocols.io.kqdg32z31v25/v1","retraction_reason":null,"samples":{},"shared_access_id":265,"show_comparison":false,"sign_info":null,"space_access":{"can_view":false,"can_edit":false,"can_remove":false,"can_add":false,"can_publish":true,"can_get_doi":true,"can_share":false,"can_move":false,"can_move_outside":false,"can_transfer":false,"can_download":false,"limited_run":false,"limited_private_links":false,"limited_blind_links":false,"is_locked":false},"space_id":5209,"state_version_id":21,"stats":{"is_voted":false,"number_of_views":1,"number_of_steps":0,"number_of_bookmarks":0,"number_of_comments":0,"number_of_bookmarked_comments":0,"number_of_steps_comments":0,"number_of_protocol_comments":0,"number_of_exports":0,"number_of_runs":0,"number_of_votes":0,"number_of_reagents":0,"number_of_equipments":0,"number_of_collections":0,"number_of_forks":{"private":0,"public":0},"number_of_accessible_forks":0},"status":{"id":1,"info":"We use this protocol and it's working"},"steps":null,"template_id":0,"title":"Treatment schemes and persistence in Colombian patients diagnosed with inflammatory arthritis after the failure of conventional disease-modifying antirheumatic drugs","title_html":"\u003cp\u003eTreatment schemes and persistence in Colombian patients diagnosed with inflammatory arthritis after the failure of conventional disease-modifying antirheumatic drugs\u003c/p\u003e","type_id":1,"units":[{"id":1,"type_id":3,"name":"µL","can_manage":0,"read_only":0},{"id":2,"type_id":3,"name":"mL","can_manage":0,"read_only":0},{"id":3,"type_id":3,"name":"L","can_manage":0,"read_only":0},{"id":4,"type_id":3,"name":"µg","can_manage":0,"read_only":0},{"id":5,"type_id":3,"name":"mg","can_manage":0,"read_only":0},{"id":6,"type_id":3,"name":"g","can_manage":0,"read_only":0},{"id":7,"type_id":3,"name":"kg","can_manage":0,"read_only":0},{"id":8,"type_id":3,"name":"ng","can_manage":0,"read_only":0},{"id":9,"type_id":3,"name":"Hz","can_manage":0,"read_only":0},{"id":10,"type_id":24,"name":"°C","can_manage":0,"read_only":0},{"id":11,"type_id":24,"name":"°К","can_manage":0,"read_only":0},{"id":12,"type_id":24,"name":"°F","can_manage":0,"read_only":0},{"id":13,"type_id":25,"name":"Mass Percent","can_manage":0,"read_only":0},{"id":14,"type_id":25,"name":"% volume","can_manage":0,"read_only":0},{"id":15,"type_id":25,"name":"Mass / % volume","can_manage":0,"read_only":0},{"id":16,"type_id":25,"name":"Parts per Million (PPM)","can_manage":0,"read_only":0},{"id":17,"type_id":25,"name":"Parts per Billion (PPB)","can_manage":0,"read_only":0},{"id":18,"type_id":25,"name":"Parts per Trillion (PPT)","can_manage":0,"read_only":0},{"id":19,"type_id":25,"name":"Mole Fraction","can_manage":0,"read_only":0},{"id":20,"type_id":25,"name":"Mole Percent","can_manage":0,"read_only":0},{"id":21,"type_id":25,"name":"Molarity (M)","can_manage":0,"read_only":1},{"id":22,"type_id":25,"name":"Molarity (M)","can_manage":0,"read_only":0},{"id":23,"type_id":25,"name":"Genome copies per ml","can_manage":0,"read_only":0},{"id":24,"type_id":3,"name":"μV","can_manage":0,"read_only":0},{"id":25,"type_id":3,"name":"ms","can_manage":0,"read_only":0},{"id":26,"type_id":3,"name":"pg","can_manage":0,"read_only":0},{"id":27,"type_id":25,"name":"Molarity dilutions","can_manage":0,"read_only":0},{"id":28,"type_id":25,"name":"millimolar (mM)","can_manage":0,"read_only":0},{"id":29,"type_id":25,"name":"micromolar (µM)","can_manage":0,"read_only":0},{"id":30,"type_id":25,"name":"nanomolar (nM)","can_manage":0,"read_only":0},{"id":31,"type_id":25,"name":"picomolar (pM)","can_manage":0,"read_only":0},{"id":32,"type_id":24,"name":"Room temperature","can_manage":0,"read_only":0},{"id":33,"type_id":30,"name":"rpm","can_manage":0,"read_only":0},{"id":34,"type_id":30,"name":"x g","can_manage":0,"read_only":0},{"id":165,"type_id":24,"name":"On ice","can_manage":0,"read_only":0},{"id":200,"type_id":32,"name":"cm","can_manage":0,"read_only":0},{"id":201,"type_id":32,"name":"mm","can_manage":0,"read_only":0},{"id":202,"type_id":32,"name":"µm","can_manage":0,"read_only":0},{"id":203,"type_id":32,"name":"nm","can_manage":0,"read_only":0},{"id":204,"type_id":25,"name":"mg/mL","can_manage":0,"read_only":0},{"id":205,"type_id":25,"name":"µg/µL","can_manage":0,"read_only":0},{"id":206,"type_id":25,"name":"% (v/v)","can_manage":0,"read_only":0},{"id":207,"type_id":3,"name":"V","can_manage":0,"read_only":0},{"id":1324,"type_id":30,"name":"rcf","can_manage":0,"read_only":0},{"id":1359,"type_id":35,"name":"Bar","can_manage":0,"read_only":0},{"id":1360,"type_id":35,"name":"Pa","can_manage":0,"read_only":0}],"uri":"treatment-schemes-and-persistence-in-colombian-pat-dm9y497w","url":"https://www.protocols.io/view/treatment-schemes-and-persistence-in-colombian-pat-dm9y497w","version_class":108568,"version_data":{"id":0,"code":"dm9y497w","version_class":108568,"parent_id":null,"parent_uri":null,"is_same_owner":false,"is_parent_public":false,"has_pending_merge_request":false,"has_approved_merge_request":false,"merge_request":null},"version_id":0,"version_uri":"treatment-schemes-and-persistence-in-colombian-pat-kqdg32z31v25/v1","versions":[{"id":108568,"title":"Treatment schemes and persistence in Colombian patients diagnosed with inflammatory arthritis after the failure of conventional disease-modifying antirheumatic drugs","title_html":"\u003cp\u003eTreatment schemes and persistence in Colombian patients diagnosed with inflammatory arthritis after the failure of conventional disease-modifying antirheumatic drugs\u003c/p\u003e","image":{"source":"https://www.protocols.io/img/default_protocol.png","webp_source":null,"placeholder":"https://www.protocols.io/img/default_protocol.png","webp_placeholder":null},"doi":"dx.doi.org/10.17504/protocols.io.kqdg32z31v25/v1","uri":"treatment-schemes-and-persistence-in-colombian-pat-dm9y497w","published_on":1727476824,"modified_on":1727476824,"version_class":108568,"version_id":0,"version_code":"dm9y497w","version_uri":"treatment-schemes-and-persistence-in-colombian-pat-kqdg32z31v25/v1","created_on":1727476255,"categories":null,"type_id":1,"creator":{"name":"Jorge Machado Alba","affiliation":"Universidad Tecnologica de Pereira - Audifarma SA","affiliation_url":null,"username":"jorge--------machado-alba","link":null,"user_image_file":{"guid":"00000000000000000000000000000001","file_name":"avatar.png","url":"https://www.protocols.io/img/avatars/001.png","mime":"image/png","size":0,"width":100,"height":100,"avg_color":"","scan_status":0,"created_at":0}},"stats":{"number_of_comments":0,"last_comment_time":0}}],"warning":""}